Pre-made Tisotumab benchmark antibody ( Whole mAb, anti-F3 therapeutic antibody, Anti-CD142/TF/TFA Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Tisotumab biosimilar, Whole mAb, Anti-F3 Antibody: Anti-CD142/TF/TFA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tisotumab vedotin, also known as HuMax-TF, HuMax®-TF-ADC or TF-011-MMAE, is an antibody-drug conjugate or ADC targeted to Tissue Factor (TF), a protein involved in tumor signaling and angiogenesis.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-582-1mg	1mg	3090
GMP-Bios-ab-582-10mg	10mg	Inquiry
GMP-Bios-ab-582-100mg	100mg	Inquiry
GMP-Bios-ab-582-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Tisotumab biosimilar, Whole mAb, Anti-F3 Antibody: Anti-CD142/TF/TFA therapeutic antibody
INN Name	Tisotumab
Target	F3
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Preregistration
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	Genmab;Seattle Genetics
Conditions Approved	na
Conditions Active	Bladder cancer;Cervical cancer;Endometrial cancer;Fallopian tube cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Solid tumours
Conditions Discontinued	na
Development Tech	na